First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018 [0.03%]
荷兰1989至2018年新诊断原发性浆细胞白血病患者的一线治疗及生存状况：基于人口的队列研究
Mirian Brink,Otto Visser,Sonja Zweegman et al.
Mirian Brink et al.
Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis [0.03%]
5号染色体长臂和7号染色体长臂缺失的髓系恶性肿瘤与极高的基因组复杂性、TP53双等位基因变异以及非常差的预后相关
Beth A Pitel,Neeraj Sharma,Cinthya Zepeda-Mendoza et al.
Beth A Pitel et al.
All-trans retinoic acid 45 mg/m2 is superior to 25 mg/m2 as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting [0.03%]
全反式维甲酸45毫克/平方米用于治疗急性早幼粒细胞白血病的首次诱导方案优于25毫克/平方米：真实世界临床病例的回顾性分析
Xinhui Zhang,Shanglong Feng,Jin Xu et al.
Xinhui Zhang et al.
MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas [0.03%]
MCL-1依赖性作为侵袭性B细胞淋巴瘤的新脆弱性
Michelle Y Wang,Tao Li,Yuan Ren et al.
Michelle Y Wang et al.
Conditional relative survival among patients with follicular lymphoma: a population-based study in the Netherlands [0.03%]
荷兰基于人群的惰性滤泡性淋巴瘤患者有条件相对生存率的研究
Manette A W Dinnessen,Otto Visser,Sanne H Tonino et al.
Manette A W Dinnessen et al.
Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13 [0.03%]
通过蛋白组学鉴定泛素受体ADRM1/Rpn13的新型抗肿瘤治疗靶点
Yan Song,Ting Du,Arghya Ray et al.
Yan Song et al.
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis [0.03%]
Venetoclax治疗t(11;14)复发/难治AL型淀粉样变性诱导血液学缓解
Vikram J Premkumar,Suzanne Lentzsch,Samuel Pan et al.
Vikram J Premkumar et al.
Venetoclax is efficacious in relapsed/refractory t(11;14) multiple myeloma, thus warranting investigation in light-chain amyloidosis (AL). This retrospective cohort includes 43 patients with previously treated AL, from 14 centers in the US ...
Genetic complexity impacts the clinical outcome of follicular lymphoma patients [0.03%]
基因复杂性影响滤泡性淋巴瘤患者的临床疗效
María García-Álvarez,Sara Alonso-Álvarez,Isabel Prieto-Conde et al.
María García-Álvarez et al.
Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma [0.03%]
弥漫性大B细胞淋巴瘤中基于基因表达谱的预后风险预测及免疫浸润特征分析
Selin Merdan,Kritika Subramanian,Turgay Ayer et al.
Selin Merdan et al.
The clinical risk stratification of diffuse large B-cell lymphoma (DLBCL) relies on the International Prognostic Index (IPI) for the identification of high-risk disease. Recent studies suggest that the immune microenvironment plays a role i...
Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden [0.03%]
瑞典人群中4243例复发/难治性弥漫大B细胞淋巴瘤（DLBCL）包括中枢神经系统复发的发病率
Sara Harrysson,Sandra Eloranta,Sara Ekberg et al.
Sara Harrysson et al.
We performed a national population-based study of all patients diagnosed with diffuse large B-cell lymphoma (DLBCL) in Sweden in 2007-2014 to assess treatment intent and risk of relapsed/refractory disease, including central nervous system ...